ciprofloxacin has been researched along with Mycoplasma dispar Infection in 16 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The sputum pharmacokinetics and clinical efficacy of ciprofloxacin in lower respiratory tract infections is reviewed." | 10.16 | Clinical efficacy of ciprofloxacin in lower respiratory tract infections. ( Pedersen, SS, 1989) |
| "The sputum pharmacokinetics and clinical efficacy of ciprofloxacin in lower respiratory tract infections is reviewed." | 6.16 | Clinical efficacy of ciprofloxacin in lower respiratory tract infections. ( Pedersen, SS, 1989) |
| "Fifty-three Mycoplasma pneumoniae strains were isolated from pediatric patients in Shanghai, China, from October 2005 to February 2008." | 1.35 | Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. ( Li, W; Liu, Y; Wang, M; Xu, X; Ye, X; Zhang, H; Zhu, D, 2009) |
| "Ciprofloxacin was administered intravenously because consolidative shadows with atelectasis increased on the chest radiograph on the 6th day." | 1.35 | [Case of macrolide-ineffective Mycoplasma pneumoniae pneumonia successfully treated with intravenous ciprofloxacin]. ( Aramaki, R; Kuraki, T; Matsumoto, T; Muraoka, K; Shiraishi, M; Sogen, K; Tanaka, M; Watanabe, K; Yamamoto, F; Yoshimura, C, 2008) |
| "The authors report two cases of transverse myelitis due to Mycoplasma pneumoniae occurring during a recent acute infection due to Epstein-Barr virus (EBV)." | 1.31 | Transverse myelitis associated with Mycoplasma pneumoniae pneumonitis: a report of two cases. ( Filice, G; Parisi, A, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (25.00) | 18.7374 |
| 1990's | 4 (25.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y | 1 |
| Ye, X | 1 |
| Zhang, H | 1 |
| Xu, X | 1 |
| Li, W | 1 |
| Zhu, D | 1 |
| Wang, M | 1 |
| Rao, SS | 1 |
| Raghunathan, R | 1 |
| Ekambaram, R | 1 |
| Raghunathan, M | 1 |
| Cardinale, F | 1 |
| Chironna, M | 1 |
| Dumke, R | 2 |
| Binetti, A | 1 |
| Daleno, C | 1 |
| Sallustio, A | 1 |
| Valzano, A | 1 |
| Esposito, S | 1 |
| Lu, A | 1 |
| Wang, L | 1 |
| Zhang, X | 1 |
| Zhang, M | 1 |
| Saegeman, V | 1 |
| Proesmans, M | 1 |
| Hantz, S | 1 |
| Garnier, F | 1 |
| Peuchant, O | 1 |
| Menetrey, C | 1 |
| Charron, A | 1 |
| Ploy, MC | 1 |
| Bébéar, C | 1 |
| Pereyre, S | 1 |
| Sogen, K | 1 |
| Tanaka, M | 1 |
| Muraoka, K | 1 |
| Matsumoto, T | 1 |
| Shiraishi, M | 1 |
| Aramaki, R | 1 |
| Yoshimura, C | 1 |
| Yamamoto, F | 1 |
| Kuraki, T | 1 |
| Watanabe, K | 1 |
| Gohara, Y | 2 |
| Arai, S | 2 |
| Akashi, A | 2 |
| Kuwano, K | 2 |
| Tseng, CC | 1 |
| Matsubara, S | 1 |
| Matumoto, M | 1 |
| Furudera, T | 1 |
| Nishimoto, M | 1 |
| Yano, T | 1 |
| Oizumi, K | 1 |
| Takeda, K | 1 |
| Yamaguchi, T | 1 |
| Parisi, A | 1 |
| Filice, G | 1 |
| Chidiac, C | 1 |
| Senneville, E | 1 |
| Mouton, Y | 1 |
| Frieden, TR | 1 |
| Mangi, RJ | 1 |
| Stubbs, R | 1 |
| Dralle, W | 1 |
| Williams, J | 1 |
| Pedersen, SS | 1 |
| Furneri, PM | 1 |
| Tempera, G | 2 |
| Chiarenza, A | 1 |
| Caccamo, F | 2 |
| Speciale, AM | 1 |
| Nicoletti, G | 2 |
| Furneri, P | 1 |
| Speciale, A | 1 |
3 reviews available for ciprofloxacin and Mycoplasma dispar Infection
| Article | Year |
|---|---|
[Value of quinolones in the treatment of lower respiratory tract infections caused by intracellular organisms, excluding mycobacteria].
Topics: Anti-Infective Agents; Chlamydia Infections; Ciprofloxacin; Enoxacin; Erythromycin; Humans; In Vitro | 1992 |
Psittacosis pneumonia.
Topics: Ciprofloxacin; Diagnosis, Differential; Humans; Male; Middle Aged; Pneumonia, Mycoplasma; Psittacosi | 1989 |
Clinical efficacy of ciprofloxacin in lower respiratory tract infections.
Topics: Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug Interactions; Humans; Lung Diseases, | 1989 |
1 trial available for ciprofloxacin and Mycoplasma dispar Infection
| Article | Year |
|---|---|
Clinical efficacy of ciprofloxacin in lower respiratory tract infections.
Topics: Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug Interactions; Humans; Lung Diseases, | 1989 |
13 other studies available for ciprofloxacin and Mycoplasma dispar Infection
| Article | Year |
|---|---|
Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.
Topics: Adhesins, Bacterial; Anti-Bacterial Agents; Child; China; Drug Resistance, Bacterial; Genes, rRNA; H | 2009 |
In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycoplasma hominis; | 2009 |
Macrolide-resistant Mycoplasma pneumoniae in paediatric pneumonia.
Topics: Anti-Bacterial Agents; C-Reactive Protein; Child; Ciprofloxacin; Community-Acquired Infections; Drug | 2011 |
Combined treatment for child refractory Mycoplasma pneumoniae pneumonia with ciprofloxacin and glucocorticoid.
Topics: Anti-Bacterial Agents; Blood Sedimentation; C-Reactive Protein; Child; Child, Preschool; Ciprofloxac | 2011 |
Management of macrolide-resistant Mycoplasma pneumoniae infection.
Topics: Anti-Bacterial Agents; Azithromycin; Child; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fem | 2012 |
Multilocus variable-number tandem-repeat analysis-confirmed emergence of a macrolide resistance-associated mutation in Mycoplasma pneumoniae during macrolide therapy for interstitial pneumonia in an immunocompromised child.
Topics: Anti-Bacterial Agents; Child; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Lung Diseases, Inte | 2012 |
[Case of macrolide-ineffective Mycoplasma pneumoniae pneumonia successfully treated with intravenous ciprofloxacin].
Topics: Adolescent; Anti-Bacterial Agents; Antibodies, Bacterial; Biomarkers; Ciprofloxacin; Humans; Macroli | 2008 |
In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Cricetinae; Drug Resistance, Mi | 1993 |
Effects of new quinolones on Mycoplasma pneumoniae-infected hamsters.
Topics: Animals; Anti-Infective Agents; Antibodies, Bacterial; Ciprofloxacin; Cricetinae; Female; Fluoroquin | 1993 |
Transverse myelitis associated with Mycoplasma pneumoniae pneumonitis: a report of two cases.
Topics: Acute Disease; Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Ciprofloxacin; Disease Suscep | 2001 |
Inappropriate use of oral ciprofloxacin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cellulitis; Ciprofloxacin; Drug Utilization; F | 1990 |
Further characterization of the in vitro and in vivo activity of ciprofloxacin against mycoplasmas.
Topics: Animals; Ciprofloxacin; Cricetinae; Culture Media; Drug Resistance, Microbial; Microbial Sensitivity | 1987 |
Longitudinal study on the therapy of Mycoplasma pneumoniae infections with ciprofloxacin on Syrian hamsters.
Topics: Animals; Ciprofloxacin; Cricetinae; Mesocricetus; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Viru | 1987 |